AI assistant
HAEMONETICS CORP — Director's Dealing 2020
Jul 22, 2020
31565_dirs_2020-07-22_3982ca4e-45fa-4fa2-b9a8-6eaf7bb7bc0f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2020-07-21
Reporting Person: Dockendorff Charles J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-07-21 | Common Stock | A | 1983 | — | Acquired | 13755 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 8568 | Indirect |
Footnotes
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3: This number includes unvested RSUs previously reported.
F4: Reflects shares held by a grantor retained annuity trust, of which Mr. Dockendorff is the sole trustee, subsequent to an exempt transfer by Mr. Dockendorff.